| 1. |
- Erlinge, David, et al.
(author)
-
Diagnosis and management of non-STEMI coronary syndromes
- 2016. - 2
-
In: Oxford Textbook of Critical Care. - : Oxford University Press. - 9780199600830 ; , s. 678-681
-
Book chapter (peer-reviewed)abstract
- Acute coronary syndromes are classified as ST segment elevation myocardial infarction (STEMI), non-STEMI (NSTEMI) or unstable angina. Most patients with NSTEMI present with a history of chest pain that has subsided spontaneously before or soon after arrival at the emergency room, but with positive cardiac markers (usually troponin T or I) indicative of myocardial infarction. NSTEMI has a risk of recurrent myocardial infarction of 15–20% and a 15% chance of 1-year mortality. Patients with non-STE-acute coronary syndromes are at similar risk as a STEMI patient at 1 year. The strongest objective signs of NSTEMI are a positive troponin and ST segment depression. NSTEMI should be acutely treated with aspirin, an adenosine diphosphate-receptor antagonist, and an anticoagulant (fondaparinux or low molecular weight heparins). NSTEMI should be investigated with coronary angiography within 72 hours. Curative treatment is percutaneous coronary intervention or coronary artery bypass grafting.
|
|
| 2. |
- Erlinge, David, et al.
(author)
-
Diagnosis and management of ST-elevation of myocardial infarction
- 2016. - 2
-
In: Oxford Textbook of Critical Care. - : Oxford University Press. - 9780199600830 - 9780199600830 ; , s. 682-687
-
Book chapter (peer-reviewed)abstract
- ST-elevation myocardial infarction (STEMI) is generally caused by a ruptured plaque that triggers local thrombus formation, which occludes the coronary artery. STEMI should be diagnosed rapidly, based on the combination of ST-segment elevation and symptoms of acute myocardial infarction. The main treatment objective is myocardial tissue reperfusion as quickly as possible. The preferred method of reperfusion is primary percutaneous coronary interventionif transport time is below 2 hours, and thrombolysis if longer STEMI patients with acute onset cardiogenic shock should be evaluated by echocardiography to exclude mechanical complications, such as flail mitral insufficiency, ventricular septal defect or tamponade. Secondary prevention includes aspirin, adenosine diphosphate receptor antagonists, statins, beta-blockers, angiotensin-converting enzymeinhibitors, and lifestyle changes.
|
|
| 3. |
- Johnsson, Åse (Allansdotter), 1966, et al.
(author)
-
Incidental findings and their handling in the Swedish CArdioPulmonary bioimage study (SCAPIS)
- 2017
-
In: Incidental Radiological Findings. - Cham : Springer International Publishing. - 0942-5373 .- 2197-4187. - 9783319425818 - 9783319425795 - 9783319826127 ; , s. 91-101
-
Book chapter (peer-reviewed)abstract
- The Swedish CArdioPulmonary bioImage Study (SCAPIS) combines the use of new imaging technologies, large-scale proteomics/metabolomics/genomics, and epidemiological analyses to extensively characterize a Swedish cohort of 30,000 men and women aged between 50 and 64 years. Its main aims are to improve risk prediction and to optimize our ability to study mechanisms of cardiopulmonary diseases. SCAPIS is currently recruiting at six sites in Sweden, and a pilot study was conducted in 2012 to test the feasibility of the comprehensive study protocol. In the planning phase, it was recognized that the detailed phenotyping used in SCAPIS would identify a large number of clinical findings in need of medical attention. This was confirmed by evaluation of results from the pilot study. Here we focus on pulmonary nodules and asymptomatic coronary artery stenosis. These clinical features were observed in a large number of participants, and the clinical handing and prognosis related to these observations are unclear. They thus posed great challenges for the study in their practical and ethical handling. This chapter describes how we developed procedures to handle these findings based on existing evidence and expert consensus as well as deliberations on ethical issues.
|
|
| 4. |
- Végvári, Ákos, et al.
(author)
-
Clinical and Biomedical Mass Spectrometry - New Frontiers in Drug Developments and Diagnosis
- 2013
-
In: Bioinformatics of Human Proteomics. - Dordrecht : Springer Netherlands. - 9789400758117 ; Translational Bioinformatics 3, s. 169-186
-
Book chapter (peer-reviewed)abstract
- Healthcare systems today are undergoing major restructuring. From the patient’s perspective, expectations focusing on high quality treatments for most common diseases – such as cancer, cardiovascular diseases, neurodegenerative diseases, diabetes, and others – have gone unmet in most countries throughout the world. Today, a number of protein expression and analysis platforms is available, which can generate large-scale maps of proteins related to healthy and diseased states. These mass spectrometry-based technologies are used on a daily basis by thousands of research laboratories around the world. The major interest is focused on discovery and validation of novel biomarkers in various diseases, as well as on targeted proteomics where quantification of multiple protein biomarkers is achieved. We present these technological developments in relation to disease diagnosis and treatment and provide two examples where significant progress has been made.
|
|
